May 27, 2016 12:49 AM ET

Pharmaceuticals

Company Overview of Taisho Pharmaceutical Co., Ltd.

Company Overview

Taisho Pharmaceutical Co., Ltd. manufactures and sells over-the-counter (OTC) medicines and health-related products. The company offers its products in the areas of CNS, diabetes, immunology/allergy, and infectious diseases; and provides self-medication products, such as Rx-to-OTC switch drugs, eye drops, cold remedy medication products, gastrointestinal medication products, energy drinks, hair re-growth treatment medication products, and foods for specified health use. It also provides prescription pharmaceutical products, such as macrolide antibiotics, injectable antibiotics, peripheral vasodilators, nonsteroidal anti-inflammatory drugs, and infection and inflammation/immune-related produc...

3-24-1, Takada

Toshima-ku

Tokyo,  170-8633

Japan

Founded in 2011

Phone:

81 3 3985 1111

Fax:

81 3 3985 8627

Key Executives for Taisho Pharmaceutical Co., Ltd.

President and Representative Director
Executive Vice President and Director
Executive Director
Senior Executive Officer and Director
Corporate Adviser and Director
Age: 78
Compensation as of Fiscal Year 2015.

Taisho Pharmaceutical Co., Ltd. Key Developments

Taisho Pharmaceutical Co., Ltd. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016

Taisho Pharmaceutical Co., Ltd. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016 . Venue: Grand Hyatt, Tokyo, Japan.

Polyphor and Taisho Pharmaceutical Enter into Research Collaboration on Novel Drug Candidates

Polyphor Ltd. announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The parties will collaborate on the identification of novel drug candidates based on Polyphor's proprietary macrocycle platform.

Taisho Pharmaceutical Co., Ltd. Announces Results from Phase III Osteoarthritis Trials

Taisho Pharmaceutical Co., Ltd. has announced results from two Phase III clinical trials with the anti-inflammatory analgesic patch formulation containing S-flurbiprofen, or TT-063, in patients with osteoarthritis. The clinical trials investigated the efficacy of applying TT-063 for two weeks, targeting 633 patients with osteoarthritis of the knee joint. The patients were divided into a group of patients to whom TT-063 was administered, and a group of patients to whom a flurbiprofen gel patch (FP) was administered as a control drug. The trials compared the two groups. The primary endpoint of the study was the change in the assessment of pain when standing. The change in this pain assessment before and after application of the patch was 40.9 mm for the TT-063 group and 30.6 mm for the FP group. As a result, the TT-063 group demonstrated significantly superior efficacy relative to the FP group. In other areas, the TT-063 group demonstrated clinically higher efficacy in terms of the assessment of pain when walking (VAS) and clinical symptoms, compared with the FP group. As a long-term trial, the clinical trials investigated the continuous application of TT-063 for 52 weeks, targeting 201 patients with osteoarthritis. The trials showed that 80% of the patients were able to continuously apply TT-063 over the trial period. Therefore, TT-063 was confirmed to possess good tolerability even during long-term use.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
AIP Corporation Asia
alphaGEN Co., Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Taisho Pharmaceutical Co., Ltd., please visit www.taisho.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.